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INTRODUCTION
• Cushing’s disease (CD) is a severe disease, associated with an increased rate of comorbidities and mortality.1 
• Remission rate after surgery of pituitary tumor is around 78%. Relapse occurs in 13% of patients within 
10 years after surgery.1 
• According to guidelines, patients who undergo noncurative surgery, or for whom surgery is not possible, 
require additional treatment, including medical therapies.2 
• Metyrapone, inhibits 11β-hydroxylase enzyme, blocking the final step of cortisol synthesis in adrenal cortex 
(Figure 1). Daily dosage ranges from 250 to 6000 mg.3
Objective
• To report four cases of patients with CD receiving long-term treatment with metyrapone up to 24 months.
Figure 1: Mode of action of metyrapone
Adapted from: Kulstad EB, et al. West J Emerg Med. 2010;11(2):161–172. Creative Commons (CC BY-NC 4.0)
PATIENTS AND METHODS
• PROMPT is an international European Phase III/IV study that commenced in 2015 (ClinicalTrial.gov registry: 
NCT02297945).
• PROMPT is the first prospective study to document the safety and efficacy of metyrapone using modern 
assay techniques, in endogenous Cushing’s syndrome over 36 weeks.
• In Belgium, four patients with CD (three women and one man) were treated with metyrapone for the duration 
of the 9-month PROMPT study. 
• One patient had received prior medical treatment with ketoconazole and cabergoline and three patients 
had received prior pituitary surgery.
• Metyrapone was individually titrated during the first 3 months of PROMPT based on urinary free cortisol 
(UFC) and/or serum cortisol performed at each visit (Figure 2).
• UFC measurements during the study was performed centrally by liquid chromatography tandem–mass 
spectrometry (LC-MS/MS) method.
• An extension period of 6 months was proposed for patients whose mean UFC normalized or did not exceed 
twice the upper limit of normal (ULN = 165 nmol/24h) (Figure 2).
• All four patients benefited after study end from further therapy with metyrapone through a medical need 
program. Three patients were treated for an additional 15 months (total 24 months) and one patient for an 
additional 12 months (total 21 months).
Figure 2: Study design
MTP: metyrapone; UFC: urinary free cortisol; ULN: upper limit of normal
RESULTS
• Centralized UFC measurements (LC-MS/MS method) showed:
 –  Baseline mean UFC value of 768 nmol/24h [range: 291–1244] fell below ULN after 3 and/or 9 months 
of treatment in three patients. 
 –  Baseline mean UFC of the fourth patient decreased by more than 50% after 9 months of therapy to 
235 nmol/24h. 
• Control of UFC levels was maintained during the study with a metyrapone dosage of between 500 mg and 
5750 mg, divided into 3–4 intakes per day (Table 1).
• Adrenocorticotropic hormone (ACTH) remained unchanged after the first 3 months of therapy, except for 
one patient who needed 5750 mg/day of metyrapone (3.2-fold increase in ACTH, Table 1). The baseline 
mean UFC was also the highest in this patient.
• Three patients maintained control of UFC levels after 24 months of treatment (as at December 2017). 
• Despite maintaining disease control with metyrapone, the fourth patient (Patient #2) decided after 21 months 
of treatment to undergo bilateral adrenalectomy.
Table 1: Efficacy results per patient during the PROMPT study
Patient 1 Patient 2 Patient 3 Patient 4
Age (years) 34 51 56 45
Mean UFC baseline (nmol/24h)* 1244 291 358 695
Mean UFC Week 12 (nmol/24h) 294 139 67 333
Mean UFC Week 36 (nmol/24h) 127 68 97 235
ACTH baseline (ng/L)† 56 10 36 10
ACTH Week 12 (ng/L) 180 6 44 11
Metyrapone baseline (mg/day) 1500 500 750 750
Metyrapone Week 36 (mg/day) 5750 1250 750 2500
*UFC ULN: 165 nmol/24h; †ACTH ULN: 46 ng/L 
ACTH: adrenocorticotropic hormone; UFC: urinary free cortisol; ULN: upper limit of normal
SAFETY AND TOLERABILITY
• Four patients had fatty deposits before treatment, which resolved in three of the patients; two patients 
developed bruising, which resolved in both patients.
• Patients experienced transient mild to moderate AEs during the 9 months of the PROMPT study: nausea 
(n=1), fatigue (n=2), tiredness (n=2), dizziness (n=1), migraine (n=1), loss of appetite (n=1) and arthralgia 
(n=1) (Table 2). 
• Safety and tolerability were acceptable during the extension period after the 9-month study. Only one woman 
(Patient #3) developed hirsutism after one year of treatment, treated with cyproterone acetate. No acne was 
observed. 
Table 2: Number of adverse events experienced per patient during the PROMPT study






Loss of appetite 1
Arthralgia 1
CONCLUSION
• Metyrapone showed good efficacy with control of cortisol based on mean UFC.
• Metapyrone has an acceptable safety and tolerability profile in the long-term management (up to 24 months) 
of four patients with CD.
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